Introduction
BioMotiv and Takeda Pharmaceutical Company has entered into Strategic Partnership,where Takeda has made a initial investment of $25million in BioMotiv.
This partnership will leverage the strengths of both organizations to identify and develop pioneering medical innovations.
The $25 million investment includes exclusive rights relating to programs sourced by BioMotiv specifically in the therapeutic areas of Immunology & Inflammation and Cardio-metabolic Diseases.
